Company intelligence / Profile preview

Iris Medicine

Ownership: Private
Development stage: Preclinical

Overview

Iris Medicine is developing a novel class of RNA therapeutics using its proprietary sbRNA™ technology to directly target the expanded repeat sequences that cause several devastating neurological diseases. The approach is designed to be allele-selective and broadly applicable across multiple indications. Lead programs are in preclinical development for Huntington’s Disease, C9orf72 ALS, and Spinocerebellar Ataxias. No clinical results have been reported yet.

Therapeutic areas: Neurology
Modalities: small binding RNAs (sbRNA)RNA therapeutics
Industry: Biotech

Drug pipeline

1 asset

Iris sbRNA

Preclinical

Partnerships

Venrock is a key investor/partner; no major pharma partnerships disclosed yet

Beyond the preview

Go deeper on Iris Medicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iris Medicine.

Explore the full profile